» Articles » PMID: 22840696

Synthesis, DNA Binding and Antileishmanial Activity of Low Molecular Weight Bis-arylimidamides

Overview
Journal Eur J Med Chem
Specialty Chemistry
Date 2012 Jul 31
PMID 22840696
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of reducing the molecular weight of the antileishmanial compound DB766 on DNA binding affinity, antileishmanial activity and cytotoxicity are reported. The bis-arylimidamides were prepared by the coupling of aryl S-(2-naphthylmethyl)thioimidates with the corresponding amines. Specifically, we have prepared new series of bis-arylimidamides which include 3a, 3b, 6, 9a, 9b, 9c, 13, and 18. Three compounds 9a, 9c, and 18 bind to DNA with similar or moderately lower affinity to that of DB766, the rest of these compounds either show quite weak binding or no binding at all to DNA. Compounds 9a, 9c, and 13 were the most active against Leishmania amazonensis showing IC(50) values of less than 1 μM, so they were screened against intracellular Leishmania donovani, showing outstanding activity with IC(50) values of 25-79 nM. Despite exhibiting little in vitro cytotoxicity these three compounds were quite toxic to mice.

Citing Articles

Escaping ESKAPE resistance: and studies of multifunctional carbamimidoyl-tethered indoles against antibiotic-resistant bacteria.

Gulia K, Hassan A, Lenhard J, Farahat A R Soc Open Sci. 2023; 10(4):230020.

PMID: 37090961 PMC: 10113819. DOI: 10.1098/rsos.230020.


Synthesis, anti-bacterial and anti-protozoal activities of amidinobenzimidazole derivatives and their interactions with DNA and RNA.

Bistrovic A, Krstulovic L, Stolic I, Drenjancevic D, Talapko J, Taylor M J Enzyme Inhib Med Chem. 2018; 33(1):1323-1334.

PMID: 30165753 PMC: 6127852. DOI: 10.1080/14756366.2018.1484733.


Evaluation of Transition Metal Complexes of Benzimidazole-Derived Scaffold as Promising Anticancer Chemotherapeutics.

Hussain A, Alajmi M, Rehman M, Khan A, Shaikh P, Khan R Molecules. 2018; 23(5).

PMID: 29883398 PMC: 6100524. DOI: 10.3390/molecules23051232.


Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Joice A, Yang S, Farahat A, Meeds H, Feng M, Li J Antimicrob Agents Chemother. 2017; 62(1).

PMID: 29061761 PMC: 5740383. DOI: 10.1128/AAC.01129-17.


Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.

Zhu X, Farahat A, Mattamana M, Joice A, Pandharkar T, Holt E Bioorg Med Chem Lett. 2016; 26(10):2551-2556.

PMID: 27048943 PMC: 4841789. DOI: 10.1016/j.bmcl.2016.03.082.


References
1.
Khanna I, Yu Y, Huff R, Weier R, Xu X, Koszyk F . Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents. J Med Chem. 2000; 43(16):3168-85. DOI: 10.1021/jm0000719. View

2.
Sundar S, Mehta H, Suresh A, Singh S, Rai M, Murray H . Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004; 38(3):377-83. DOI: 10.1086/380971. View

3.
Hayashi Y, Yamaguchi S, Cha W, Kim D, Shinokubo H . Synthesis of directly connected BODIPY oligomers through Suzuki-Miyaura coupling. Org Lett. 2011; 13(12):2992-5. DOI: 10.1021/ol200799u. View

4.
Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling R . Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol. 2007; 5(11):873-82. DOI: 10.1038/nrmicro1748. View

5.
Collar C, Zhu X, Werbovetz K, Boykin D, Wilson W . Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies. Bioorg Med Chem. 2011; 19(15):4552-61. PMC: 3164838. DOI: 10.1016/j.bmc.2011.06.026. View